Clinical Trial Update: A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating PLB1001 enteric capsules for IDH-mutant glioblastoma with ZM fusion in glioblastoma patients; the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Idh-mutant Glioblastoma

Drugs mentioned

• PLB1001

Snippet

Sponsor: Beijing Pearl Biotechnology Limited Liability Company | Conditions: Glioblastoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING